Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization

Journal of Cardiac Surgery

Volumn 20, Issue 1, 2005, Pages 42-51

  Iqbal, Omer ^a   Tobu, M ^a   Aziz, S ^b   Gerdisch, M ^a   Da Valle, M ^a   Demir, M ^c   Hoppensteadt, D A ^a   Ahmad, S ^a   Walenga, J M ^a   Fareed, J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Washington Adventist Hospital   (United States)

^c TRAKYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; ECARIN; LEPIRUDIN; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR;

ADULT; AGED; ANALYZER; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; BOLUS INJECTION; CASE REPORT; CENTRIFUGAL ANALYZER; CORONARY ARTERY RECANALIZATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INFUSION; DRUG MONITORING; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; MALE; OFF PUMP CORONARY ARTERY RECANALIZATION; OFF PUMP CORONARY SURGERY; PARTIAL THROMBOPLASTIN TIME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CORONARY ARTERY BYPASS, OFF-PUMP; ENDOPEPTIDASES; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 19944432432     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0886-0440.2005.200316.x     Document Type: Article

References (27)

1. Harvey RP, Degryse E, Stefani L, et al: Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986;83:1084-1088.
2. Stone SR, Hofsteenge J: Kinetics of inhibition of thrombin by hirudin. Biochemistry 1986;25:4622-4628.
3. Stringer KA, Lindenfeld J: Hirudins: Antithrombotic anticoagulants. Ann Pharmacother 1992;26:1535-1540.
4. Scheil F, Vuillemenot A, Kramarz P, et al: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Ann J Haematol 1995;50:25-29.
5. Nand S: Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Haematol 1993;43:310-311.
6. Ortel TL, Chong BH: New treatment options for heparin-induced thrombocytopenia. Semin Haematol 1998;35:26-34.
7. Riess FC, Lower C, Seelig C: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265-267.
8. Potzsch B, Iversen S, Riess FC: Recombinant hirudin as an anticoagulant in open-heart surgery: A case report. Ann Haematol 1994;68:A53.
9. Fidlar E, Jaques LB: The effect of commercial heparin on the platelet count. J Lab Clin Med 1948;33:1410-1423.
10. Chong BH, Pitney WR, Castaldi PA: Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982;2:1246-1249.
11. Babcock RB, Dumper CW, Scharfman WB: Heparin-induced immune thrombocytopenia. N Engl J Med 1976;295:237-241.
12. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
13. Kelton JG, Sheridan D, Santos A, et al: Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988;72:925-930.
14. Warkentin TE, Hayward CPM, Smith CA, et al: Determination of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120:371-379.
15. Greinacher A, Michels I, Kiefel V, et al: A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia. Thromb Haemost 1991;66:734-736.
16. Markwardt F: The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23.
17. Marbet GA, Verstraete M, Kienast J, et al: Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364-372.
18. Meiring SM, Lotter SM, Badenhorst PN, et al: Sites of elimination and pharmacokinetics of recombinant [131I] lepirudin in baboons. J Pharm Sci 1999;88:523-529.
19. Zoldhelyi P, Webster MWI, Fuster V, et al: Recombinant hirudin in patients with chronic, stable coronary artery disease: Safety, half-life and effects on coagulation parameters. Circulation 1993;88:2015-2022.
20. Verstraete M, Noormohamed M, Kienast J, et al: Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. J Am Coll Cardiol 1993;22:1080-1088.
21. Stringer KA, Lindenfeld J. Hirudins: Antithrombin anticoagulants. Ann Pharmacother 1992;26:1535-1540.
22. Tripodi A, Chantarangkul V, Arbini AA, et al: Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993;70:286-288.
23. Nowak G, Bucha E: A new method for the therapeutical monitoring of hirudin. Thromb Haemost 1993;69(Suppl):A1306.
24. Buscha E, Nowak G: The ecarin clotting time (ECT): The first specific method suited for quick determination of direct thrombin inhibitors in whole blood, plasma, and body fluids. Int Angiol 1995;14(Suppl 1):174.
25. Antman EM for the TIMI9a investigators. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI9a) trial. Circulation 1994;90:1624-1630.
26. Gygax D, Botta L, Erhat M, et al: Immunoassays in monitoring biotechnological drugs. Ther Drug Monit 1996;18:405-409.
27. Liebe V, Bruckmann M, Fischer KG, et al: Biological relevance of anti-recombinant hirudin antibodies-Results from in vitro and in vivo studies. Semin Thromb Haemost 2002;28(5):483-489.